Allspring Global Investments Holdings LLC Has $3.04 Million Position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)
Allspring Global Investments Holdings LLC Has $3.04 Million Position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)
Allspring Global Investments Holdings LLC grew its position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Rating) by 4.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 293,204 shares of the biotechnology company's stock after buying an additional 11,484 shares during the quarter. Allspring Global Investments Holdings LLC owned 0.19% of Ironwood Pharmaceuticals worth $3,037,000 as of its most recent SEC filing.
根据AllSpring Global Investments Holdings LLC最近提交给美国证券交易委员会(Securities And Exchange Commission)的文件，该公司第三季度将其在铁木制药公司(Ironwood PharmPharmticals，Inc.，简称：IRWD-GET)的持仓增加了4.1%。该机构投资者在本季度额外购买了11,484股后，持有293,204股这家生物技术公司的股票。根据新浪美国证券交易委员会的最新申请，AllSpring Global Investments Holdings LLC持有铁木制药0.19%的股份，价值3,037,000美元。
Several other hedge funds and other institutional investors also recently made changes to their positions in IRWD. Gladius Capital Management LP acquired a new position in shares of Ironwood Pharmaceuticals in the 2nd quarter valued at approximately $55,000. Banque Cantonale Vaudoise bought a new stake in shares of Ironwood Pharmaceuticals during the 2nd quarter valued at approximately $58,000. Captrust Financial Advisors grew its holdings in shares of Ironwood Pharmaceuticals by 441.7% during the 2nd quarter. Captrust Financial Advisors now owns 6,690 shares of the biotechnology company's stock valued at $77,000 after purchasing an additional 5,455 shares during the last quarter. Lazard Asset Management LLC bought a new stake in shares of Ironwood Pharmaceuticals during the 1st quarter valued at approximately $78,000. Finally, Quantbot Technologies LP bought a new stake in shares of Ironwood Pharmaceuticals during the 1st quarter valued at approximately $109,000.
其他几家对冲基金和其他机构投资者最近也改变了他们在IRWD的头寸。Gladius Capital Management LP在第二季度收购了Ironwood PharmPharmticals股票的新头寸，价值约5.5万美元。Canonale Vaudoise银行在第二季度购买了Ironwood PharmPharmticals的新股份，价值约58,000美元。CapTrust Financial Advisors在第二季度增持了441.7%的铁木制药股票。CapTrust Financial Advisors现在持有这家生物技术公司6690股股票，价值7.7万美元，在上个季度又购买了5455股。Lazard Asset Management LLC在第一季度购买了Ironwood PharmPharmticals的新股份，价值约7.8万美元。最后，Quantbot Technologies LP在第一季度购买了Ironwood PharmPharmticals的新股份，价值约10.9万美元。
Ironwood Pharmaceuticals Trading Down 1.6 %
铁木制药股价下跌1.6%
IRWD opened at $11.41 on Wednesday. Ironwood Pharmaceuticals, Inc. has a fifty-two week low of $9.73 and a fifty-two week high of $12.95. The company has a debt-to-equity ratio of 0.67, a current ratio of 25.78 and a quick ratio of 25.78. The firm has a market capitalization of $1.75 billion, a price-to-earnings ratio of 12.01 and a beta of 0.96. The company's 50 day moving average price is $11.89 and its two-hundred day moving average price is $11.39.
IRWD周三开盘报11.41美元。Ironwood PharmPharmticals，Inc.股价为52周低点9.73美元，52周高点12.95美元。该公司的债务权益比为0.67，流动比率为25.78，速动比率为25.78。该公司的市值为17.5亿美元，市盈率为12.01倍，贝塔系数为0.96。该公司的50日移动均线价格为11.89美元，200日移动均线价格为11.39美元。
Insider Transactions at Ironwood Pharmaceuticals
铁木制药的内幕交易
In other news, CEO Thomas A. Mccourt sold 110,962 shares of the business's stock in a transaction that occurred on Thursday, January 5th. The shares were sold at an average price of $12.07, for a total value of $1,339,311.34. Following the transaction, the chief executive officer now owns 712,440 shares in the company, valued at approximately $8,599,150.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 13.10% of the company's stock.
在其他新闻方面，首席执行官托马斯·A·麦考特在1月5日星期四的一次交易中出售了110,962股该公司的股票。这些股票的平均价格为12.07美元，总价值为1,339,311.34美元。交易完成后，这位首席执行官现在拥有该公司712,440股票，价值约8,599,150.80美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可以通过美国证券交易委员会网站。公司内部人士持有该公司13.10%的股份。
Analyst Ratings Changes
分析师评级发生变化
Separately, StockNews.com lowered shares of Ironwood Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Saturday, December 17th. One equities research analyst has rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $14.67.
另外，StockNews.com在12月17日星期六的一份报告中将Ironwood PharmPharmticals的股票评级从“强力买入”下调至“买入”。一位股票研究分析师将该股的评级定为持有，三位分析师将该公司的评级定为买入。根据MarketBeat.com的数据，该股目前的平均评级为“适度买入”，共识目标价为14.67美元。
Ironwood Pharmaceuticals Company Profile
铁木制药公司简介
(Get Rating)
(获取评级)
Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union.
Ironwood PharmPharmticals，Inc.是一家保健公司，专注于胃肠(GI)产品的开发和商业化。它在美国和墨西哥以Linzess的名义销售利纳克肽，在加拿大和欧盟以Constella的名义销售利纳克肽，这是一种鸟苷环化酶C型激动剂，用于治疗患有便秘(IBS-C)或慢性特发性便秘(CIC)的成年人。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Ironwood Pharmaceuticals (IRWD)
- Does it Matter Folks Aren't "Starry-Eyed" Over Pepsi's New Soda?
- Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?
- Can Alaska Air Continue Soaring Above The Airline Industry?
- Insulet Has Potential To Gain More Than Analysts Are Forecasting
- Cathie Wood Is Buying These Stocks, Should You?
- 免费获取StockNews.com关于铁木制药的研究报告(IRWD)
- 人们对百事可乐的新苏打水不感兴趣，这有什么关系吗？
- 强生的突破：盈利能提振股市吗？
- 阿拉斯加航空能否继续在航空业之上高歌猛进？
- Insulet有潜力获得超过分析师预测的收益
- 凯西·伍德正在购买这些股票，你应该这样做吗？
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接受Ironwood PharmPharmticals Daily新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Ironwood PharmPharmticals和相关公司的最新新闻和分析师评级的每日简要摘要。